Company Overview
Werewolf Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immune responses, representing a specialized focus within the broader healthcare sector. Specifically, it functions within the biotechnology industry, which is characterized by high research and development costs and long product development cycles before potential commercialization. The company currently holds a market capitalization of $37.94M, while reported annual revenue is not available in the provided data, and the employee count is listed as N/A. These valuation and operational scale metrics indicate that Werewolf Therapeutics is a smaller-cap entity with limited historical revenue data available for public analysis, suggesting it is likely in a pre-commercial or early-stage development phase where traditional revenue-based scaling has not yet occurred.
Financial Health
The company reports a net income of $-60,822,000 over the trailing twelve months, with EBITDA standing at $-59,043,000, while revenue is not available for calculation. The significant gap between the reported net income loss and the EBITDA figure reveals a cost structure heavily impacted by non-operating expenses or interest costs, as EBITDA attempts to exclude such items to show operational cash generation. Free cash flow stands at $-18,276,376, indicating that the company is currently burning cash to fund its operations and research initiatives rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated profitable sales to establish positive gross or operating profitability. Regarding capital structure, the company holds $57.05M in cash against $9.44M in debt, resulting in a debt-to-equity ratio of 38.04. This high debt-to-equity ratio suggests a leveraged balance sheet relative to equity, yet the substantial cash reserve provides a buffer against the reported debt obligations. The current ratio is 1.62, which indicates that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Return on Equity is -123.9% and Return on Assets is -38.6%, metrics that reveal the company is currently destroying value per share and per asset dollar due to its deep losses. These negative return figures are typical for early-stage biotechnology firms but signal that management effectiveness is currently measured by the preservation of cash rather than profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed as -0.79. The negative forward P/E implies that analysts or data providers expect earnings to remain negative in the near future, preventing the calculation of a traditional positive earnings multiple. The price-to-book ratio is 1.53, which indicates that the market values the company at 1.53 times its book value, suggesting a premium over the net asset value often seen in companies with valuable intellectual property or potential pipeline assets. Price-to-sales ratio and EV/EBITDA are provided as 0.16 for EV/EBITDA, while the price-to-sales ratio is not available; the low EV/EBITDA of 0.16 suggests a very low valuation relative to earnings power, though this is distorted by the significant negative earnings. The stock has traded between a 52-week low of $0.53 and a 52-week high of $2.38. Without a specific current price provided in the facts, the valuation context relies on this range to show the stock has experienced significant volatility within the year, potentially fluctuating by over 300% from its low to its high. The beta value is not available, which means the specific volatility relative to the broader market cannot be quantified for this specific security in the current dataset.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning historical growth trajectories cannot be calculated from the available data. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue as both growth rates are unavailable for comparison. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Since the company pays no dividends, it retains all earnings or cash reserves to reinvest into growth activities such as drug development rather than distributing income to shareholders. The overall growth and income profile is defined by a complete lack of historical growth data and a zero-dividend policy, focusing entirely on capital preservation and future product development rather than current shareholder returns.